WithdrawnNot Applicable

Patients Who Receive 131 I-MIBG

Stopped: difficult enrollment, no subjects consented or enrolled

United States0Started 2021-03-10

Plain-language summary

This study is for patients who have have neuroblastoma, pheochromocytoma, or paraganglioma that has come back (relapsed) after treatment or has not gotten better (refractory) with standard treatment. The purpose of this study is to evaluate quality of life and response rate to 131 I-MIBG treatment.

Who can participate

Age range1 Year – 30 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Written informed consent, and assent where applicable, and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
✓. Age greater than or equal to 1 years and less than or equal to 30 years at the time of therapy.
✓. Subject is scheduled to receive 131 I-MIBG therapy.
✓. Diagnosis of refractory, progressive or relapsed Neuroblastoma, Malignant Paraganglioma, Malignant Pheochromocytoma or other Neuroendocrine Tumors.
✓. As determined by the enrolling physician, ability of the subject and parent/caregiver to understand and comply with study procedures for the entire length of the study.

What they're measuring

Change in Quality of Life

Timeframe: For up to 2 years after treatment with 131 I-MIBG

Trial details

NCT IDNCT04770831

SponsorWake Forest University Health Sciences

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12

View on ClinicalTrials.gov More Brain and Nervous System trials